Sinocelltech Trials - LARVOL Sigma

43 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Anpingxi (ripertamab) / Sinocelltech

NCT06405100: Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD

Not yet recruiting

Supportive care+Prednisone, Control group, Supportive care+Tacrolimus+Ripertamab, Test group 1, Supportive care+Ripertamab, Test group 2

Air Force Military Medical University, China, First Affiliated Hospital Xi'an Jiaotong University, Second Affiliated Hospital of Xi'an Jiaotong University, The Second Affiliated Hospital of Air Force Military Medical University, Shaanxi Provincial People's Hospital, Shaanxi Provincial Hospital of Chinese Medicine

Minimal Change Disease

04/26

04/27

RIPERT-CIDP, NCT06858722: Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy

Not yet recruiting

175

ripertamab, Placebo

Zhongming Qiu

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

06/27

12/27

ChiCTR2400087275: Efficacy and Safety of Ripertamab With or Without Other Drugs in B-cell Non-Hodgkin's Lymphomas

Recruiting

N/A

400

none

Institute of Hematology and Oncology, Harbin The First Hospital; Institute of Hematology and Oncology, Harbin The First Hospital, self-raised

Lymphomas

Ancain (omfiloctocog alfa) / Sinocelltech

ChiCTR2100052152: Real-World evidence of SCT800 for prophylaxis treatment based on health resource among patients with moderate or servere hemophilia A in China: a prospective observational study

Not yet recruiting

300

None

Hematology Hospital of Chinese Academy of Medical Sciences; Shenzhou Cell Engineering Co., Ltd., self-raised

hemophilia A

ChiCTR2200067033: The outcome comparison of immune tolerance induction therapy using SCT800 combined with Daratumumab or SCT800 alone in hemophilia A adolescents and adults with high titer inhibitor: a randomized controlled trial

Not yet recruiting

SCT800 combined with Daratumumab ;SCT800 alone

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College; Hematology Hospital of Chinese Academy of Medical Sciences, Sinocelltech Ltd

hemophilia A

NCT03947567: Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.

Recruiting

240

RoW

Recombinant Human Coagulation FVIII, SCT800

Sinocelltech Ltd.

Hemophilia A

04/25

NCT05888870: ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Recruiting

RoW

SCT800 and Daratumumab, Immune tolerance induction combine anti-CD38, SCT800, Immune tolerance induction only

Institute of Hematology & Blood Diseases Hospital, China, Sinocelltech Ltd.

Hemophilia A With Inhibitor

12/26

ChiCTR2300068747: Design of a randomized, controlled trial of continuous versus bolus infusions under preoperative pharmacokinetic-guided by Recombinant Human Coagulation Factor VIII (Omfiloctocog alfa, SCT800) in haemophilia A

Not yet recruiting

N/A

perioperative continuous infusion ;perioperative bolus infusions

Nanfang Hospital, Southern Medical University; Nanfang Hospital, Southern Medical University, Supported by Project of Drug Clinical Evaluate Research of Chinese Pharmaceutical Association NO.CPA-Z06-ZC-2021-004 ；Shenzhou Cell Engineering Co., Ltd.

Haemophilia orthopaedic disorders

Ambezhu (bevacizumab biosimilar) / Sinocelltech

SCT-I10A-C301, NCT04560894: SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma

Active, not recruiting

2/3

405

RoW

SCT-I10A, SCT510, Sorafenib 200mg

Sinocelltech Ltd.

Hepatocellular Carcinoma

04/24

09/24

SCT200 / Sinocelltech

NCT04229537: Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC

Not yet recruiting

SCT-I10A, SCT200, Chemotherapy

Sinocelltech Ltd.

Esophageal Squamous Cell Carcinoma, Colorectal Cancer

08/22

12/22

NCT05552807: SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting

120

RoW

SCT-I10A, SCT200, paclitaxel, docetaxel

Sinocelltech Ltd.

Head and Neck Squamous Carcinoma

09/23

Anjiarun (adalimumab biosimilar) / Sinocelltech

NCT03927352: The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis

Active, not recruiting

330

RoW

SCT630, Adalimumab

Sinocelltech Ltd.

Psoriasis

12/21

12/22

ChiCTR1900023482: Pharmacokinetics and Safety of SCT630 in Healthy Subjects: a Randomized, Double-blind, Single Dose Clinical Phase I Study

Recruiting

146

T,40mg/0.8mL ;R,40mg/0.8mL

Beijing Shijitan Hospital Capital Medical University; Sinocelltech Ltd., Sinocelltech Ltd.

Autoimmune diseases

Anyouping (finotonlimab) / Sinocelltech

ChiCTR2500103475: Finotonlimab with taxane/platinum chemotherapy or cetuximab as first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world study

Not yet recruiting

300

None; None; None

Shanghai East Hospital; Shanghai East Hospital, self-funded

Head and Neck Squamous Carcinom

NCT04171284: SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer

Terminated

188

RoW

SCT-I10, human PD-1 monoclonal antibody, Docetaxel, Placebo

Sinocelltech Ltd.

Squamous-cell Non-Small-cell Lung Cancer

02/23

LONG'E, NCT07040072: Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC

Not yet recruiting

RoW

Stapokibart and Finotonlimab

Beijing Tongren Hospital, Keymed Biosciences Co.Ltd, Sinocelltech Ltd.

HNSCC

06/27

06/28

NCT07009470: A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence

Active, not recruiting

N/A

130

RoW

Finotonlimab (an anti-PD-1 monoclonal antibody) and Anbeizhu (a bevacizumab biosimilar), TACE

Tongji Hospital

HCC

04/28

10/28

SCTA01 / Sinocelltech

MASP3, NCT04683328: The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care

Not yet recruiting

2/3

560

SCTA01, SCTA01 Placebo

Sinocelltech Ltd.

Covid19

05/21

11/21

NCT04644185: The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19

Terminated

2/3

103

US, RoW

SCTA01, Recombinant anti-SARS-CoV-2 spike protein monoclonal antibody, Placebo, SCTA01 excipients

Sinocelltech Ltd.

Covid19

12/21

02/22

MAOP3, NCT04709328: To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19

Not yet recruiting

2/3

690

SCTA01, Placebo

Sinocelltech Ltd.

COVID-19, SARS-CoV-2

01/22

03/22

SCT510A (bevacizumab intravitreal biosimilar) / Sinocelltech

NCT05480293: This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD

Recruiting

446

RoW

Ranibizumab, SCT510A

Sinocelltech Ltd.

Wet Age-related Macular Degeneration

07/25

08/25

NCT04564937: The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)

Not yet recruiting

1/2

SCT510A

Sinocelltech Ltd.

Wet Age-related Macular Degeneration

04/22

10/22

recombinant 14 valent human papillomavirus vaccine (SCT1000) / Sinocelltech

NCT06041061: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years

Active, not recruiting

18000

RoW

Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）, placebo

Sinocelltech Ltd., Guangxi Center for Disease Control and Prevention, Henan Center for Disease Control and Prevention, Sichuan Center for Disease Control and Prevention, Shanxi Center for Disease Control and Prevention, Yunnan Center for Disease Control and Prevention

HPV InfectioN, HPV-Related Carcinoma

03/24

08/28

NCT05060484: A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Recruiting

1800

RoW

SCT1000, Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells), GardasilÂ®9, GardasilÂ®, placebo

Sinocelltech Ltd.

Interventional, Prevention, Randomized

05/22

07/22

NCT04921111: A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Recruiting

240

RoW

SCT1000, Recombinant 14 valent Human Papillomavirus Vaccine, Gardasil®9, Recombinant 9 valent human papillomavirus vaccine, placebo, aluminium phosphate, Gardasil®, Recombinant 4 valent human papillomavirus vaccine

Sinocelltech Ltd.

HPV Infection Vaccine Safety SCT1000

07/22

10/22

bivalent recombinant trimeric S protein (SCTV01C) / Sinocelltech

SCTV01C-E-01-UAE-1, NCT05323461: A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines

Active, not recruiting

1800

RoW

SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine, Comirnaty

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

10/22

05/23

NCT05239975: A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine

Withdrawn

240

SCTV01C, Comirnaty

Sinocelltech Ltd.

COVID-19, SARS-CoV2 Infection

07/22

02/23

NCT05238454: A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged â‰¥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine

Not yet recruiting

600

SCTV01C, Sinopharm inactivated COVID-19 vaccine, Comirnaty

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

07/22

12/22

NCT05239806: A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged â‰¥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine

Not yet recruiting

400

SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine, Comirnaty

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

08/22

08/23

NCT05308602: A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years

Withdrawn

480

SCTV01C, SCTV01E, mRNA vaccine manufactured by Pfizer or Moderna, Sinopharm inactivated COVID-19 vaccine

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

08/22

08/23

NCT05043311: The Safety and Immunogenicity of SCTV01C in Healthy Population Aged â‰¥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.

Recruiting

1/2

300

RoW

SCTV01C, Placebo

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

06/22

01/23

NCT05043285: The Safety and Immunogenicity of SCTV01C in Healthy Population Aged â‰¥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.

Recruiting

1/2

300

RoW

SCTV01C, Placebo

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

06/22

01/23

NCT05148091: The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults

Completed

1/2

478

RoW

SCTV01C, Adjuvant, SCT-VA02B, Saline

Sinocelltech Ltd.

COVID-19

08/23

SCTV01E / Sinocelltech

NCT05683561: A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People

Not yet recruiting

6000

CoronaVac, SCTV01E

Sinocelltech Ltd.

COVID-19 SARS-CoV-2 Infection

08/23

08/24

SCTV01E-MRCT-1, NCT05308576: A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years

Active, not recruiting

10000

RoW

SCTV01E, Placebo

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

05/23

04/24

NCT05238441: A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged â‰¥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine

Not yet recruiting

360

SCTV01E, Comirnaty

Sinocelltech Ltd.

COVID-19, Sars-CoV-2 Infection

06/22

05/23

NCT05329051: A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged â‰¥18 Years

Not yet recruiting

400

SCTV01E, Comirnaty

Sinocelltech Ltd.

SARS-CoV-2 Infection, COVID-19

09/22

03/23

NCT05345873: A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years

Not yet recruiting

300

SCTV01E, mRNA-1273

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

10/22

04/23

NCT05522829: A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years

Not yet recruiting

400

SCTV01E-1 on D0, SCTV01E-1 on D28, SCTV01E-1 on D150, SCTV01E on D0, SCTV01E on D28, SCTV01E on D150, SCTV01E-1 on D120, SCTV01E on D120

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

12/22

12/23

SCTV01E, NCT05652543: A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine

Completed

518

RoW

SCTV01E, Placebo (normal saline)

Sinocelltech Ltd.

COVID-19 Pandemic

01/24

NCT05933512: A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines

Not yet recruiting

600

SCTV01E-2, SCTV01E

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

12/23

11/24

SCTC21C / Sinocelltech

NCT06774664: A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

Not yet recruiting

1/2

RoW

SCTC21C

Sinocelltech Ltd.

IgA Nephropathy

09/27

03/29

NCT06252298: A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

Recruiting

RoW

SCTC21C

Sinocelltech Ltd.

Relapsed or Refractory Hematologic Malignancies

08/25

02/27

SCTB03 / Sinocelltech

No trials found

SCT-I04 / Sinocelltech

No trials found

SCTB54 / Sinocelltech

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Anpingxi (ripertamab) / Sinocelltech

NCT06405100: Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD

Not yet recruiting

Supportive care+Prednisone, Control group, Supportive care+Tacrolimus+Ripertamab, Test group 1, Supportive care+Ripertamab, Test group 2

Minimal Change Disease

04/26

04/27

RIPERT-CIDP, NCT06858722: Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy

Not yet recruiting

175

ripertamab, Placebo

Zhongming Qiu

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

06/27

12/27

ChiCTR2400087275: Efficacy and Safety of Ripertamab With or Without Other Drugs in B-cell Non-Hodgkin's Lymphomas

Recruiting

N/A

400

none

Institute of Hematology and Oncology, Harbin The First Hospital; Institute of Hematology and Oncology, Harbin The First Hospital, self-raised

Lymphomas

Ancain (omfiloctocog alfa) / Sinocelltech

ChiCTR2100052152: Real-World evidence of SCT800 for prophylaxis treatment based on health resource among patients with moderate or servere hemophilia A in China: a prospective observational study

Not yet recruiting

300

None

Hematology Hospital of Chinese Academy of Medical Sciences; Shenzhou Cell Engineering Co., Ltd., self-raised

hemophilia A

Not yet recruiting

SCT800 combined with Daratumumab ;SCT800 alone

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College; Hematology Hospital of Chinese Academy of Medical Sciences, Sinocelltech Ltd

hemophilia A

NCT03947567: Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.

Recruiting

240

RoW

Recombinant Human Coagulation FVIII, SCT800

Sinocelltech Ltd.

Hemophilia A

04/25

NCT05888870: ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Recruiting

RoW

SCT800 and Daratumumab, Immune tolerance induction combine anti-CD38, SCT800, Immune tolerance induction only

Institute of Hematology & Blood Diseases Hospital, China, Sinocelltech Ltd.

Hemophilia A With Inhibitor

12/26

Not yet recruiting

N/A

perioperative continuous infusion ;perioperative bolus infusions

Haemophilia orthopaedic disorders

Ambezhu (bevacizumab biosimilar) / Sinocelltech

SCT-I10A-C301, NCT04560894: SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma

Active, not recruiting

2/3

405

RoW

SCT-I10A, SCT510, Sorafenib 200mg

Sinocelltech Ltd.

Hepatocellular Carcinoma

04/24

09/24

SCT200 / Sinocelltech

NCT04229537: Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC

Not yet recruiting

SCT-I10A, SCT200, Chemotherapy

Sinocelltech Ltd.

Esophageal Squamous Cell Carcinoma, Colorectal Cancer

08/22

12/22

NCT05552807: SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting

120

RoW

SCT-I10A, SCT200, paclitaxel, docetaxel

Sinocelltech Ltd.

Head and Neck Squamous Carcinoma

09/23

Anjiarun (adalimumab biosimilar) / Sinocelltech

NCT03927352: The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis

Active, not recruiting

330

RoW

SCT630, Adalimumab

Sinocelltech Ltd.

Psoriasis

12/21

12/22

ChiCTR1900023482: Pharmacokinetics and Safety of SCT630 in Healthy Subjects: a Randomized, Double-blind, Single Dose Clinical Phase I Study

Recruiting

146

T,40mg/0.8mL ;R,40mg/0.8mL

Beijing Shijitan Hospital Capital Medical University; Sinocelltech Ltd., Sinocelltech Ltd.

Autoimmune diseases

Anyouping (finotonlimab) / Sinocelltech

ChiCTR2500103475: Finotonlimab with taxane/platinum chemotherapy or cetuximab as first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world study

Not yet recruiting

300

None; None; None

Shanghai East Hospital; Shanghai East Hospital, self-funded

Head and Neck Squamous Carcinom

NCT04171284: SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer

Terminated

188

RoW

SCT-I10, human PD-1 monoclonal antibody, Docetaxel, Placebo

Sinocelltech Ltd.

Squamous-cell Non-Small-cell Lung Cancer

02/23

LONG'E, NCT07040072: Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC

Not yet recruiting

RoW

Stapokibart and Finotonlimab

Beijing Tongren Hospital, Keymed Biosciences Co.Ltd, Sinocelltech Ltd.

HNSCC

06/27

06/28

NCT07009470: A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence

Active, not recruiting

N/A

130

RoW

Finotonlimab (an anti-PD-1 monoclonal antibody) and Anbeizhu (a bevacizumab biosimilar), TACE

Tongji Hospital

HCC

04/28

10/28

SCTA01 / Sinocelltech

MASP3, NCT04683328: The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care

Not yet recruiting

2/3

560

SCTA01, SCTA01 Placebo

Sinocelltech Ltd.

Covid19

05/21

11/21

NCT04644185: The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19

Terminated

2/3

103

US, RoW

SCTA01, Recombinant anti-SARS-CoV-2 spike protein monoclonal antibody, Placebo, SCTA01 excipients

Sinocelltech Ltd.

Covid19

12/21

02/22

MAOP3, NCT04709328: To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19

Not yet recruiting

2/3

690

SCTA01, Placebo

Sinocelltech Ltd.

COVID-19, SARS-CoV-2

01/22

03/22

SCT510A (bevacizumab intravitreal biosimilar) / Sinocelltech

NCT05480293: This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD

Recruiting

446

RoW

Ranibizumab, SCT510A

Sinocelltech Ltd.

Wet Age-related Macular Degeneration

07/25

08/25

NCT04564937: The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)

Not yet recruiting

1/2

SCT510A

Sinocelltech Ltd.

Wet Age-related Macular Degeneration

04/22

10/22

recombinant 14 valent human papillomavirus vaccine (SCT1000) / Sinocelltech

NCT06041061: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years

Active, not recruiting

18000

RoW

Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）, placebo

HPV InfectioN, HPV-Related Carcinoma

03/24

08/28

NCT05060484: A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Recruiting

1800

RoW

SCT1000, Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells), GardasilÂ®9, GardasilÂ®, placebo

Sinocelltech Ltd.

Interventional, Prevention, Randomized

05/22

07/22

NCT04921111: A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Recruiting

240

RoW

Sinocelltech Ltd.

HPV Infection Vaccine Safety SCT1000

07/22

10/22

bivalent recombinant trimeric S protein (SCTV01C) / Sinocelltech

SCTV01C-E-01-UAE-1, NCT05323461: A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines

Active, not recruiting

1800

RoW

SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine, Comirnaty

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

10/22

05/23

NCT05239975: A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine

Withdrawn

240

SCTV01C, Comirnaty

Sinocelltech Ltd.

COVID-19, SARS-CoV2 Infection

07/22

02/23

NCT05238454: A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged â‰¥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine

Not yet recruiting

600

SCTV01C, Sinopharm inactivated COVID-19 vaccine, Comirnaty

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

07/22

12/22

Not yet recruiting

400

SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine, Comirnaty

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

08/22

08/23

NCT05308602: A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years

Withdrawn

480

SCTV01C, SCTV01E, mRNA vaccine manufactured by Pfizer or Moderna, Sinopharm inactivated COVID-19 vaccine

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

08/22

08/23

NCT05043311: The Safety and Immunogenicity of SCTV01C in Healthy Population Aged â‰¥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.

Recruiting

1/2

300

RoW

SCTV01C, Placebo

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

06/22

01/23

NCT05043285: The Safety and Immunogenicity of SCTV01C in Healthy Population Aged â‰¥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.

Recruiting

1/2

300

RoW

SCTV01C, Placebo

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

06/22

01/23

NCT05148091: The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults

Completed

1/2

478

RoW

SCTV01C, Adjuvant, SCT-VA02B, Saline

Sinocelltech Ltd.

COVID-19

08/23

SCTV01E / Sinocelltech

NCT05683561: A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People

Not yet recruiting

6000

CoronaVac, SCTV01E

Sinocelltech Ltd.

COVID-19 SARS-CoV-2 Infection

08/23

08/24

SCTV01E-MRCT-1, NCT05308576: A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years

Active, not recruiting

10000

RoW

SCTV01E, Placebo

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

05/23

04/24

NCT05238441: A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged â‰¥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine

Not yet recruiting

360

SCTV01E, Comirnaty

Sinocelltech Ltd.

COVID-19, Sars-CoV-2 Infection

06/22

05/23

NCT05329051: A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged â‰¥18 Years

Not yet recruiting

400

SCTV01E, Comirnaty

Sinocelltech Ltd.

SARS-CoV-2 Infection, COVID-19

09/22

03/23

NCT05345873: A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years

Not yet recruiting

300

SCTV01E, mRNA-1273

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

10/22

04/23

NCT05522829: A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years

Not yet recruiting

400

SCTV01E-1 on D0, SCTV01E-1 on D28, SCTV01E-1 on D150, SCTV01E on D0, SCTV01E on D28, SCTV01E on D150, SCTV01E-1 on D120, SCTV01E on D120

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

12/22

12/23

SCTV01E, NCT05652543: A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine

Completed

518

RoW

SCTV01E, Placebo (normal saline)

Sinocelltech Ltd.

COVID-19 Pandemic

01/24

NCT05933512: A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines

Not yet recruiting

600

SCTV01E-2, SCTV01E

Sinocelltech Ltd.

COVID-19, SARS-CoV-2 Infection

12/23

11/24

SCTC21C / Sinocelltech

NCT06774664: A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

Not yet recruiting

1/2

RoW

SCTC21C

Sinocelltech Ltd.

IgA Nephropathy

09/27

03/29

NCT06252298: A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

Recruiting

RoW

SCTC21C

Sinocelltech Ltd.

Relapsed or Refractory Hematologic Malignancies

08/25

02/27

SCTB03 / Sinocelltech

No trials found

SCT-I04 / Sinocelltech

No trials found

SCTB54 / Sinocelltech

No trials found

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites